Clinical Trials on Major Depressive Disorder in United Kingdom

Total 60326 results

Janssen Research & Development, LLC

Terminated

A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD)

Finland, Germany, Korea, Republic of, United States, Taiwan, Estonia, India, Italy, Mexico
Takeda

Completed

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Major Depressive Disorder

United States
BRC Operations Pty. Ltd.

Unknown

International Study to Predict Optimised Treatment - in Depression (iSPOT-D)

Major Depressive Disorder

United States, Australia, Netherlands, New Zealand, South Africa
Targacept Inc.

Completed

TC-5214 as add-on the Treatment of Major Depressive Disorder

Depression | Major Depressive Disorder

United States, India
Abbott Medical Devices

Terminated

Deep Brain Stimulation for Major Depressive Disorder

Depressive Disorder, Major | Unipolar Depression

United States, Canada, United Kingdom
Bristol-Myers Squibb
Otsuka America Pharmaceutical

Completed

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Perry Renshaw

Completed

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Major Depressive Disorder

United States
Bristol-Myers Squibb
Otsuka America Pharmaceutical

Completed

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Sunovion

Withdrawn

Major Depressive Disorder With Mixed Features (RESOLVE2)

Major Depressive Disorder

United States
Alkermes, Inc.

Completed

A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Pfizer

Completed

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Chile, Mexico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression

Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder

United States
University of Michigan

Recruiting

The CARE (Collaborative Adolescent Running Experience) Project (CARE)

Depression | Anxiety | Bipolar Disorder | Major Depressive Disorder

United States
Biogen

Terminated

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Major Depressive Disorder

United States
Bayside Health

Recruiting

Nitrous Oxide for the Treatment of Major Depressive Disorder

Depression | Major Depressive Disorder

Australia, United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

Depressive Disorder, Major

United States, Spain, Italy, United Kingdom
The University of Texas Health Science Center,...

Terminated

The UTHealth Ketamine Project

Bipolar Disorder | Major Depressive Disorder | Treatment Resistant Depression

United States
Intra-Cellular Therapies, Inc.

Completed

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Czechia, Slovakia, Hungary, India
David Steffens
National Institute of Mental Health (NIMH)

Recruiting

Predictors of Cognitive Outcomes in Geriatric Depression (NBOLD)

Stress | Cognitive Change | Major Depressive Disorder | Neuroticism

United States
Mclean Hospital
Harvard University; Cambridge Health Alliance

Completed

Treatment Resistant Geriatric Depression in Primary Care

Major Depressive Disorder

United States
GlaxoSmithKline

Completed

Patient Tolerability Study of GSK163090

Depressive Disorder, Major | Major Depressive Disorder (MDD)

United States
Alto Neuroscience

Recruiting

Phase 2b Study of ALTO-100 in MDD

Major Depressive Disorder

United States
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Intra-Cellular Therapies, Inc.

Active, not recruiting

Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Germany, Poland, Finland, Sweden, Argentina
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Northstar Neuroscience

Terminated

Assessment of the Safety and Effectiveness of Cortical Stimulation in Subjects With Major Depressive Disorder (PROSPECT)

Depressive Disorder | Depression

United States
Relmada Therapeutics, Inc.

Recruiting

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD (RELIGHT)

Depression | Major Depressive Disorder

United States
Alto Neuroscience

Recruiting

Study of ALTO-300 in MDD

Major Depressive Disorder

United States
Pfizer

Completed

A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD

Major Depressive Disorder

United States, Mexico
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Major Depressive Disorder

United States, South Africa, Poland, Ukraine, Japan, Russian Federation, Latvia
Hoffmann-La Roche

Completed

MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Major Depressive Disorder

Germany, United States, Taiwan, Mexico, Poland, Russian Federation, Chile, Japan, Romania
Sirtsei Pharmaceuticals, Inc.

Completed

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Labopharm Inc.

Completed

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

Major Depressive Disorder

United States, Canada
University of California, San Francisco
San Francisco Veterans Affairs Medical Center

Completed

Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression (PRS)

Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Major Depressive Disorder

Mexico, United States, Argentina, Canada
AstraZeneca

Completed

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders (PEARL)

Major Depressive Disorder

United States
Euthymics BioScience, Inc.

Completed

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Major Depressive Disorder

United States
H. Lundbeck A/S

Completed

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

Irritability | Major Depressive Disorder

United States
Relmada Therapeutics, Inc.

Recruiting

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-II)

Depression | Major Depressive Disorder

United States
Forest Laboratories

Completed

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States, Canada
GlaxoSmithKline

Terminated

A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder (Orvepitant MDD)

Depressive Disorder

United States, Canada
Forest Laboratories

Completed

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Pfizer

Completed

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Chile
AstraZeneca

Completed

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders (OPAL)

Major Depressive Disorder

United States
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

Major Depressive Disorder

United States, Puerto Rico
AstraZeneca

Completed

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo and Active Control in Major Depressive Disorder (DIAMOND)

Major Depressive Disorder

United States

3

Subscribe